Anakinra: An emerging option for refractory idiopathic recurrent pericarditis: A systematic review of published evidence

Journal of Cardiovascular Medicine

Volumn 17, Issue 4, 2016, Pages 256-262

  Lazaros, George ^a,b   Imazio, Massimo ^a   Brucato, Antonio ^c   Vassilopoulos, Dimitrios ^b   Vasileiou, Panagiotis ^b   Gattorno, Marco ^d   Tousoulis, Dimitrios ^b   Martini, Alberto ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Anakinra; Autoinflammatory diseases; Efficacy; Idiopathic; Recurrent pericarditis; Safety

Indexed keywords

C REACTIVE PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC RECURRENT PERICARDITIS; PERICARDITIS; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; EVIDENCE BASED MEDICINE; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; PERICARDITIS; RECURRENCE;

EID: 84960088686     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000266     Document Type: Review

References (41)

1. Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014-systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2014; Epub ahead of print. PubMed PMID: 25000255.
2. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014; 383:2232-2237.
3. Imazio M, Brucato A, Cemin R, et al., ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013; 369:1522-1528.
4. Imazio M. Treatment of recurrent pericarditis. Rev Esp Cardiol (Engl Ed) 2014; 67:345-348.
5. Imazio M, Adler Y. Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev 2013; 18:355-360.
6. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712-722.
7. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation 2010; 121:916-928.
8. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008; 118:667-671.
9. Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M. Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 2010; 9:436-440.
10. Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012; 101:525-531.
11. Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60:264-268.
12. Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis 2014; 73:2215-2217; doi: 10.1136/annrheumdis-2014-205990.
13. Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr 2014; 164:1425-1431.
14. Emmi G, Barnini T, Silvestri E, Milco D'Elios M, Emmi L, Prisco D. A new case of idiopathic recurrent acute pericarditis due to R104Q mutation in TNFRSF1A successfully treated with anakinra: expanding the questions. Clin Exp Rheumatol 2014; 32:297.
15. Picco P, Naselli A, Pala G, Marsciani A, Buoncompagni A, Martini A. Recurrent pericarditis in Myhre syndrome. Am J Med Genet A 2013; 161:1164-1166.
16. Camacho-Lovillo M, Méndez-Santos A. Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra). Pediatr Cardiol 2013; 34:1293-1294.
17. Scardapane A, Brucato A, Chiarelli F, Breda L. Efficacy of an interleukin-1b receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr Cardiol 2013; 34:1989-1991.
18. Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 2010; 28:802.
19. Baszis KW, Singh G, White A, Thatayatikom A. Recurrent cardiac tamponade in a child with newly diagnosed systemic-onset juvenile idiopathic arthritis. J Clin Rheumatol 2012; 18:304-306.
20. Vassilopoulos D, Lazaros G, Tsioufis C, Vasileiou P, Stefanadis C, Pectasides D. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol 2012; 160:66-68.
21. Scott IC, Hajela V, Hawkins PN, Lachmann HJ. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J Cardiol Cases 2011; 4:e93-e97.
22. Nieto González JC, Monteagudo Saez I, López-Longo FJ, Serrano B, Mata Martínez C, Carreño Pérez L. Idiopathic recurrent pericarditis treated successfully with tumour necrosis factor alpha blocking agents (anti-TNF-a). Clin Exp Rheumatol 2013; 31:776-778.
23. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117:2670-2683.
24. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-3732.
25. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36:1118-1125.
26. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 2001; 15:87-97.
27. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39:1003-1018.
28. Dinarello C. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-3732.
29. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19:382-384.
30. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323:86-89.
31. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 1986; 163:1363-1375.
32. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147.
33. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin-1. Immunol Today 1994; 15:562-566.
34. Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012; 32:295-299.
35. Lazaros G, Vlachopoulos C, Stefanadis C. Idiopathic recurrent pericarditis: searching for Ariadne's thread. Hellenic J Cardiol 2009; 50:345-351.
36. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014; 10:135-147.
37. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002; 87:93-96.
38. Clarke JB. Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol 2010; 196:453-474.
39. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 (Suppl. 2):ii29-ii35.
40. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011; 7:639-652.
41. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo controlled trials. Ann Rheum Dis 2009; 68:25-32.